1. Does Adding Zevalin® to Reduced Intensity Regimen (RIC) of Fludarabine and Melphalan Improve Outcome of Patients with Relapsed/Refractory B-Cell Lymphoma Who Were Chemoresistant and FDG PET Positive at the Time of Allo-HCT? 
Auayporn Nademanee, MD, Andrew Raubitschek, MD, Tracey Stiller, M.S., Jennifer Simpson, B.S., Joycelynne Palmer, PhD, Jilian Cai, MD, PhD, Firoozeh Sahebi, MD, Leslie Popplewell, MD, FACP, Robert Chen, MD, Stephen J. Forman, MD 
Biology of Blood and Marrow Transplantation 
Volume 22, Issue 3, Pages S341-S342 (March 2016)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Biology of Blood and Marrow Transplantation 2016 22, S341-S342DOI: (10
Biology of Blood and Marrow Transplantation  , S341-S342DOI: ( /j.bbmt )
Copyright © Terms and Conditions